Brokerages Set Privia Health Group, Inc. (NASDAQ:PRVA) PT at $27.62

Shares of Privia Health Group, Inc. (NASDAQ:PRVA) have been given a consensus recommendation of “Moderate Buy” by the twelve ratings firms that are presently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation and ten have issued a buy recommendation on the company. The average 12 month price target among analysts that have issued a report on the stock in the last year is $26.58.

A number of research analysts recently weighed in on the company. Canaccord Genuity Group dropped their price target on Privia Health Group from $41.00 to $37.00 and set a “buy” rating on the stock in a research note on Tuesday, March 19th. Citigroup initiated coverage on shares of Privia Health Group in a research note on Monday, April 22nd. They set a “buy” rating and a $25.00 price target for the company. JPMorgan Chase & Co. reduced their price objective on shares of Privia Health Group from $38.00 to $30.00 and set an “overweight” rating for the company in a report on Wednesday, March 6th. Jefferies Financial Group assumed coverage on shares of Privia Health Group in a report on Monday, February 26th. They issued a “buy” rating and a $25.00 target price on the stock. Finally, Barclays started coverage on Privia Health Group in a research note on Wednesday, March 6th. They set an “equal weight” rating and a $22.00 price target for the company.

Privia Health Group Stock Performance

Shares of PRVA opened at $18.74 on Friday. The firm has a market cap of $2.22 billion, a PE ratio of 98.64, a price-to-earnings-growth ratio of 2.56 and a beta of 0.81. Privia Health Group has a 52-week low of $17.54 and a 52-week high of $30.15. The business’s 50 day moving average price is $19.62 and its two-hundred day moving average price is $21.09.

Privia Health Group (NASDAQ:PRVA) last released its earnings results on Tuesday, February 27th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.02). The company had revenue of $440.80 million for the quarter, compared to analyst estimates of $425.81 million. Privia Health Group had a net margin of 1.39% and a return on equity of 3.97%. The firm’s revenue was up 21.0% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.14 EPS. Research analysts predict that Privia Health Group will post 0.26 EPS for the current fiscal year.

Insider Transactions at Privia Health Group

In related news, EVP Thomas Bartrum sold 2,252 shares of the firm’s stock in a transaction dated Tuesday, April 30th. The stock was sold at an average price of $18.42, for a total transaction of $41,481.84. Following the transaction, the executive vice president now directly owns 103,862 shares of the company’s stock, valued at approximately $1,913,138.04. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CEO Parth Mehrotra sold 12,219 shares of the company’s stock in a transaction on Tuesday, April 30th. The shares were sold at an average price of $18.42, for a total transaction of $225,073.98. Following the completion of the sale, the chief executive officer now directly owns 261,640 shares in the company, valued at approximately $4,819,408.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Thomas Bartrum sold 2,252 shares of the firm’s stock in a transaction on Tuesday, April 30th. The stock was sold at an average price of $18.42, for a total transaction of $41,481.84. Following the completion of the sale, the executive vice president now directly owns 103,862 shares in the company, valued at approximately $1,913,138.04. The disclosure for this sale can be found here. In the last three months, insiders sold 31,783 shares of company stock worth $582,886. 14.20% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Privia Health Group

Several hedge funds and other institutional investors have recently modified their holdings of PRVA. Park Place Capital Corp increased its holdings in Privia Health Group by 115.4% during the 1st quarter. Park Place Capital Corp now owns 2,492 shares of the company’s stock valued at $49,000 after purchasing an additional 1,335 shares during the period. Benjamin Edwards Inc. grew its position in shares of Privia Health Group by 44.9% in the 4th quarter. Benjamin Edwards Inc. now owns 3,239 shares of the company’s stock worth $75,000 after buying an additional 1,003 shares during the last quarter. Covestor Ltd increased its stake in shares of Privia Health Group by 8.3% during the third quarter. Covestor Ltd now owns 6,703 shares of the company’s stock valued at $154,000 after buying an additional 514 shares during the period. Benjamin F. Edwards & Company Inc. bought a new position in shares of Privia Health Group during the fourth quarter valued at approximately $158,000. Finally, International Assets Investment Management LLC lifted its stake in Privia Health Group by 2,721.7% in the fourth quarter. International Assets Investment Management LLC now owns 7,139 shares of the company’s stock worth $164,000 after acquiring an additional 6,886 shares during the period. 94.48% of the stock is owned by institutional investors.

Privia Health Group Company Profile

Privia Health Group, Inc operates as a national physician-enablement company in the United States. The company collaborates with medical groups, health plans, and health systems to optimize physician practices, enhance patient experiences, and reward doctors for delivering care in-person and virtual settings.